CL2020003256A1 - Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos. - Google Patents

Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos.

Info

Publication number
CL2020003256A1
CL2020003256A1 CL2020003256A CL2020003256A CL2020003256A1 CL 2020003256 A1 CL2020003256 A1 CL 2020003256A1 CL 2020003256 A CL2020003256 A CL 2020003256A CL 2020003256 A CL2020003256 A CL 2020003256A CL 2020003256 A1 CL2020003256 A1 CL 2020003256A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
cd3xmuc16
cancer
treatment
Prior art date
Application number
CL2020003256A
Other languages
English (en)
Spanish (es)
Inventor
Alison Crawford
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2020003256A1 publication Critical patent/CL2020003256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2020003256A 2018-06-21 2020-12-16 Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos. CL2020003256A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
CL2020003256A1 true CL2020003256A1 (es) 2021-04-30

Family

ID=67254001

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003256A CL2020003256A1 (es) 2018-06-21 2020-12-16 Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos.

Country Status (26)

Country Link
US (1) US11254752B2 (https=)
EP (2) EP4424712A3 (https=)
JP (1) JP7403480B2 (https=)
KR (1) KR102870971B1 (https=)
CN (1) CN112312970B (https=)
AU (1) AU2019290170B2 (https=)
BR (1) BR112020025476A2 (https=)
CA (1) CA3103887A1 (https=)
CL (1) CL2020003256A1 (https=)
DK (1) DK3810281T3 (https=)
EA (1) EA202190088A1 (https=)
ES (1) ES2984972T3 (https=)
FI (1) FI3810281T3 (https=)
HU (1) HUE067985T2 (https=)
IL (1) IL279251B2 (https=)
MA (2) MA71708A (https=)
MX (2) MX2020013905A (https=)
MY (1) MY202134A (https=)
PH (1) PH12020552115A1 (https=)
PL (1) PL3810281T3 (https=)
PT (1) PT3810281T (https=)
RS (1) RS65886B1 (https=)
SG (1) SG11202012137UA (https=)
TW (2) TW202504917A (https=)
WO (1) WO2019246356A1 (https=)
ZA (1) ZA202007599B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
IL300835A (en) * 2020-09-02 2023-04-01 Genmab As Antibody therapy
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2022197907A2 (en) * 2021-03-18 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors
EP4397320A1 (en) 2021-08-31 2024-07-10 Nihon Medi-Physics Co., Ltd. Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product
EP4437003A1 (en) * 2021-11-24 2024-10-02 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
US20230312718A1 (en) * 2022-01-07 2023-10-05 Regeneron Pharmaceuticals, Inc Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
JP2025504795A (ja) 2022-01-10 2025-02-19 ナンチン リーズ バイオラブス カンパニー，リミティド 抗体及びその用途
US20250195645A1 (en) * 2022-03-16 2025-06-19 Daiichi Sankyo Company, Limited Combination of multispecific molecule and immune checkpoint inhibitor
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
LT3394103T (lt) * 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
TWI910495B (zh) 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos

Also Published As

Publication number Publication date
MA52962B1 (fr) 2024-10-31
JP2021528423A (ja) 2021-10-21
JP7403480B2 (ja) 2023-12-22
CN112312970B (zh) 2025-05-23
EP4424712A2 (en) 2024-09-04
RS65886B1 (sr) 2024-09-30
EP3810281B1 (en) 2024-07-24
TW202504917A (zh) 2025-02-01
TWI890661B (zh) 2025-07-21
MA71708A (fr) 2025-05-30
WO2019246356A1 (en) 2019-12-26
TW202005985A (zh) 2020-02-01
AU2019290170A1 (en) 2021-01-07
DK3810281T3 (da) 2024-08-19
EP4424712A3 (en) 2024-11-13
HUE067985T2 (hu) 2024-12-28
FI3810281T3 (fi) 2024-08-14
CN112312970A (zh) 2021-02-02
MY202134A (en) 2024-04-05
PH12020552115A1 (en) 2021-08-02
CA3103887A1 (en) 2019-12-26
SG11202012137UA (en) 2021-01-28
ES2984972T3 (es) 2024-10-31
MX2025008444A (es) 2025-08-01
MA52962A (fr) 2021-04-28
US11254752B2 (en) 2022-02-22
IL279251B1 (en) 2025-11-01
IL279251A (en) 2021-01-31
BR112020025476A2 (pt) 2021-03-16
IL279251B2 (en) 2026-03-01
PL3810281T3 (pl) 2024-11-04
PT3810281T (pt) 2024-08-02
ZA202007599B (en) 2025-02-26
KR20210023981A (ko) 2021-03-04
AU2019290170B2 (en) 2026-04-02
US20190389966A1 (en) 2019-12-26
MX2020013905A (es) 2021-03-09
KR102870971B1 (ko) 2025-10-16
EP3810281A1 (en) 2021-04-28
EA202190088A1 (ru) 2021-03-22

Similar Documents

Publication Publication Date Title
CL2020003256A1 (es) Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos.
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2018007613A (es) Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
CL2021000131A1 (es) Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos.
DOP2021000238A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
MX2020004573A (es) Terapia de combinacion con agonistas de ox40 dirigidos.
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CO2019012356A2 (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso
CL2019003095A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos.
CR20190266A (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
MX2025003354A (es) Anticuerpos que se unen a 5t4
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2024011298A (es) Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
CO2021017688A2 (es) Anticuerpo biespecífico contra α-syn/igf1r y uso del mismo
MX2024008055A (es) Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.